BioNTech SE 22UA.F Stock
BioNTech SE Price Chart
BioNTech SE 22UA.F Financial and Trading Overview
| BioNTech SE stock price | 81.6 EUR |
| Previous Close | 104.75 EUR |
| Open | 102.05 EUR |
| Bid | 103.25 EUR x N/A |
| Ask | 103.5 EUR x N/A |
| Day's Range | 102.05 - 103.65 EUR |
| 52 Week Range | 92 - 185.9 EUR |
| Volume | 226 EUR |
| Avg. Volume | 1.97K EUR |
| Market Cap | 24.89B EUR |
| Beta (5Y Monthly) | 0.217213 |
| PE Ratio (TTM) | 3.9761357 |
| EPS (TTM) | 3.83 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | June 2, 2022 |
| 1y Target Est | 334.89 EUR |
22UA.F Valuation Measures
| Enterprise Value | 13.06B EUR |
| Trailing P/E | 3.9761357 |
| Forward P/E | 2.349329 |
| PEG Ratio (5 yr expected) | -0.23 |
| Price/Sales (ttm) | 2.0383418 |
| Price/Book (mrq) | 1.2284164 |
| Enterprise Value/Revenue | 1.069 |
| Enterprise Value/EBITDA | 1.607 |
Trading Information
BioNTech SE Stock Price History
| Beta (5Y Monthly) | 0.217213 |
| 52-Week Change | -14.45% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 185.9 EUR |
| 52 Week Low | 92 EUR |
| 50-Day Moving Average | 104.89 EUR |
| 200-Day Moving Average | 131.62 EUR |
22UA.F Share Statistics
| Avg. Volume (3 month) | 1.97K EUR |
| Avg. Daily Volume (10-Days) | 1.21K EUR |
| Shares Outstanding | 240.99M |
| Float | 87.36M |
| Short Ratio | N/A |
| % Held by Insiders | 65.11% |
| % Held by Institutions | 18.18% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 51.07% |
| Operating Margin (ttm) | 65.97% |
| Gross Margin | 85.28% |
| EBITDA Margin | 66.53% |
Management Effectiveness
| Return on Assets (ttm) | 23.76% |
| Return on Equity (ttm) | 34.48% |
Income Statement
| Revenue (ttm) | 12.21B EUR |
| Revenue Per Share (ttm) | 50.29 EUR |
| Quarterly Revenue Growth (yoy) | -80.00000000000000000000000000000000% |
| Gross Profit (ttm) | N/A |
| EBITDA | 8.13B EUR |
| Net Income Avi to Common (ttm) | 6.24B EUR |
| Diluted EPS (ttm) | 25.98 |
| Quarterly Earnings Growth (yoy) | -86.40% |
Balance Sheet
| Total Cash (mrq) | 12.5B EUR |
| Total Cash Per Share (mrq) | 51.88 EUR |
| Total Debt (mrq) | 209.8M EUR |
| Total Debt/Equity (mrq) | 1.04 EUR |
| Current Ratio (mrq) | 12.951 |
| Book Value Per Share (mrq) | 84.092 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 8.85B EUR |
| Levered Free Cash Flow (ttm) | 8.31B EUR |
Profile of BioNTech SE
| Country | Germany |
| State | N/A |
| City | Mainz |
| Address | An der Goldgrube 12 |
| ZIP | 55131 |
| Phone | 49 6131 9084 0 |
| Website | https://www.biontech.de |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 5100 |
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
Q&A For BioNTech SE Stock
What is a current 22UA.F stock price?
BioNTech SE 22UA.F stock price today per share is 81.6 EUR.
How to purchase BioNTech SE stock?
You can buy 22UA.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioNTech SE?
The stock symbol or ticker of BioNTech SE is 22UA.F.
Which industry does the BioNTech SE company belong to?
The BioNTech SE industry is Biotechnology.
How many shares does BioNTech SE have in circulation?
The max supply of BioNTech SE shares is 240.99M.
What is BioNTech SE Price to Earnings Ratio (PE Ratio)?
BioNTech SE PE Ratio is 21.30548300 now.
What was BioNTech SE earnings per share over the trailing 12 months (TTM)?
BioNTech SE EPS is 3.83 EUR over the trailing 12 months.
Which sector does the BioNTech SE company belong to?
The BioNTech SE sector is Healthcare.